TITLE

BIOMARIN FILES CTX TO CONDUCT CLINICAL TRIAL OF VIBRIOLYSIN

PUB. DATE
August 2001
SOURCE
Worldwide Biotech;Aug2001, Vol. 13 Issue 8, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that BioMarin Pharmaceutical Inc. has filed a Clinical Trial Exemption application with the Medicines Control Agency in the United Kingdom for permission to conduct a human clinical trial of Vibriolysin Topical in patients with serious burns.
ACCESSION #
4964878

 

Related Articles

  • BIOMARIN INITIATES PHASE 2 CLINICAL TRIAL OF ARYPLASE.  // Biotech Business;Jun2002, Vol. 15 Issue 6, p1 

    Reports on the initiation by Biomarin Pharmaceutical Inc. of the second phase clinical trial for its Aryplase drug.

  • BioMarin/Genzyme to Conduct Confirmatory Trial of Aldurazyme.  // Biotech Business;Jan2000, Vol. 13 Issue 1, p1 

    Reports that BioMarin Pharmaceutical Inc. and joint venture partner Genzyme General will conduct a confirmatory clinical trial of Aldurazyme enzyme replacement therapy for mucopolysaccharidosis-I.

  • Laronidase.  // BioDrugs;2002, Vol. 16 Issue 4, p316 

    Adis Comments BioMarin Pharmaceutical is developing laronidase, recombinant α-L-iduronidase enzyme replacement therapy for the treatment of mucopolysaccharidosis I (MPS-I) [the most severe form of this is called Hurler syndrome]. The company has received US and European orphan drug...

  • BIOMARIN GETS POSITIVE DATA FROM VIBRILASE PHASE 1B TRIAL.  // Biotech Business;Oct2004, Vol. 17 Issue 10, p6 

    Reports on the results of a Phase 1b clinical trial of Vibrilase, an investigational topical enzyme for the treatment of serious burns, conducted by Novato, California-based BioMarin Pharmaceutical Inc. Background on the open-label clinical trial; Information on the efficacy, safety and...

  • BioMarin's Much-Anticipated GALNS Trial Starts in MPS IVA. Boggs, Jennifer // BioWorld Today;2/2/2011, Vol. 22 Issue 22, p1 

    The article reports on a clinical trial launched by BioMarin Pharmaceutical Inc. for its enzyme replacement therapy (ERT) N-acetylgaalctosamine 6-sulfatase (GALNS). The study will enroll patients with mucopolysacharidosis Type IVA. The disease is characterized by excessive storage of karatan...

  • Galsulfase.  // Drugs in R&D;2005, Vol. 6 Issue 5, p312 

    Galsulfase [Aryplaseâ„¢, arylsulfatase B, BM 102, Naglazymeâ„¢, rhASB, recombinant human N-acetylgalactosamine-4-sulfatase, recombinant human arylsulfatase B] is under development with BioMarin Pharmaceutical as an enzyme replacement therapy for the treatment of mucopolysaccharidosis...

  • Clinic Roundup.  // BioWorld Today;12/1/2011, Vol. 22 Issue 232, p3 

    The article presents updates on clinical trials as of December 2011. Acucela Inc. has confirmed that Phase Ia showed that oral administration of ACU-4429 was well tolerated in healthy volunteers. Top-line results from a pilot Phase I/II study were released by Adeona Pharmaceuticals Inc. and the...

  • Futility Analysis Derails BioMarin and LJP's Phase III Riquent Trial. Morrison, Trista // BioWorld Today;2/13/2009, Vol. 20 Issue 29, p1 

    The article reports on the decision of BioMarin Pharmaceutical Inc. and La Jolla Pharmaceutical Co. to stop their Phase III trial of Requent in systemic lupus erythematosus after analysis showed it would be futile to continue. The structuring by BioMarin means the company has only shelled out...

  • BioMarin Not Minding the Gap; License Deal All in Good Time. Osborne, Randy // BioWorld Insight;6/15/2009, Vol. 17 Issue 24, p3 

    The article discusses the business performance of BioMarin Pharmaceutical Inc. and the developments related to its early stage drugs. It reports the results of phase one trials on BioMarin's phenylketonuria drug PEG-PAL and the Morquio Syndrome drug BMN-110, and mentions the failure of its lupus...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics